Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study
Qiang Yin,Peng Li,Peng Wang,Zhen Zhang,Qun Liu,Zengfeng Sun,Wenliang Li,Li Ma,Xiaoguang Wang
DOI: https://doi.org/10.2147/ott.s345439
IF: 4
2021-12-31
OncoTargets and Therapy
Abstract:Qiang Yin, Peng Li, Peng Wang, Zhen Zhang, Qun Liu, Zengfeng Sun, Wenliang Li, Li Ma, Xiaoguang Wang Department of Neurosurgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China Correspondence: Xiaoguang Wang; Li Ma Tel +86 22 2334 0123 2061; +86 22 2334 0123 2062 Fax +86 22 2335 9337 Email ; Purpose: The performance of alectinib and crizotinib in untreated anaplastic lymphoma kinase (ALK)-positive patients with non-small-cell lung cancer (NSCLC) and symptomatic and synchronic brain metastases is largely unknown. This retrospective study assessed the effectiveness of alectinib and crizotinib, together with intracranial therapies in a cohort of these patients. Patients and Methods: This study included 34 previously untreated ALK-positive NSCLC patients with three or fewer intracranial metastases. Of these patients, 13 received oral alectinib 600 mg twice daily, and 21 received oral crizotinib 250 mg twice daily, until progressive disease, unacceptable toxicity, or death. All intracranial metastases were treated with craniotomy, CyberKnife, or both. Results: Median overall progression-free survival (PFS) was 32.8 months (95% CI 24.4– 41.2 months) in patients treated with alectinib and 8.0 months (95% CI 7.3– 8.7 months) in patients treated with crizotinib. Median PFS of brain lesions was not yet reached with alectinib (95% CI 30.1 months–not estimated) and was 8.5 months (95% CI 7.2– 12.3 months) with crizotinib. Median PFS of lung lesions was 38.5 months (95% CI 27.5– 49.5 months) with alectinib and 9.2 months (95% CI 7.4– 11.0 months) with crizotinib. Median overall survival was not yet reached with alectinib (95% CI 31.0 months–not estimated) and 30.3 months (95% CI 27.3– 37.1 months) with crizotinib. Conclusion: Compared with crizotinib, alectinib showed superior efficacy and lower toxicity in the treatment of ALK-positive patients with NSCLC and symptomatic and synchronic brain metastases. The inclusion of intracranial therapies such as craniotomy or CyberKnife further improved the brain PFS and overall survival of these patients. Keywords: alectinib, crizotinib, non-small-cell lung cancer, brain metastasis, intracranial therapies Non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement is a distinct subset of lung cancer, with an incidence ranging from 2% to 7%. 1 Echinoderm microtubule associated protein-like 4 gene ( EML4 ) is the absolute dominant ALK fusion partner in NSCLC patients. The EML4-ALK fusion results in the constitutive activation of a pro-proliferative cascade. 2 These ALK-positive tumors tend to have a more aggressive phenotype with multiple metastatic sites at diagnosis compared with other NSCLC types. In particular, patients with ALK-positive NSCLC are usually at higher risk for developing brain metastases, with and the central nervous system (CNS) being the most common site of disease progression. 3,4 At the time of diagnosis, up to 35% of these patients had brain metastases, with the rates at 2 and 3 years being 45.5% and 58.4%, respectively. 5 Crizotinib is a first-generation ALK inhibitor that showed greater efficacy than chemotherapy in ALK-positive NSCLC patients in the PROFILE 1014 trial. 6 Subsequent evaluation found that a significant proportion of crizotinib-treated patients developed CNS metastases, probably because the blood–brain barrier is relatively impermeable to crizotinib. Alectinib is a second-generation and highly CNS-active ALK inhibitor that was shown to be highly effective in several Phase III clinical trials. 3,7,8 For example, the ALEX trial (NCT02075840), which enrolled 303 untreated ALK-positive patients with stage IIIB–IV NSCLC, found that investigator-assessed mature progression-free survival (PFS) was significantly longer in patients treated with alectinib than with crizotinib [hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.32–0.58]; that median PFS was 34.8 months with alectinib versus 10.9 months with crizotinib; and that median overall survival (OS) was not reached with alectinib versus 57.4 months with crizotinib (stratified HR 0.67, 95% CI 0.46–0.98, P =0.0376). 9 The PFS benefit of alectinib was lower but maintained in patients with baseline CNS metastases, with the median PFS being 25.4 months (95% CI 9.2 months–not estimated) with alectinib and 7.4 months (95% CI 6.6–9.6 months) with crizotinib (HR 0.37, 95% CI 0.23–0.58)]. However, the proportion of ALK-positive NSCLC patients with baseline CNS metastases was relatively low in the ALEX an -Abstract Truncated-
oncology,biotechnology & applied microbiology